Microsoft

The strategy could be applied more widely to study the development of other organ systems, and will benefit from new single-cell gene expression analysis technology.

US Patent 8,521,441. Method and computer product for reducing flurophore-specific bias. Inventors: Roland Stoughton, Hongyue Dai. Assignee: Microsoft

US Patent 8,494,779. Method for screening essential metabolites in growth of microorganisms Inventors: Sang Yup Lee, Hawoong Jeong, Tae Yong Kim, Pan-Jun Kim, Kwang Ho Lee. Assignee: Korea Advanced Institute of Science and Technology

US Patent 8,467,974. System, method, and computer software for the presentation and storage of analysis results. Inventors: Shantanu Kaushikkar, Teresa Webster, Rui Mei, Linda McAllister. Assignee: Affymetrix

US Patent 8,417,462. System and method for identifying complex patterns of amino acids. Inventors: Samuel Bogoch, Elenore Bogoch, Samuel Winston Bogoch, Anne Elenore Borsanyi. Assignee: Not Listed

Increasing activity from sequencing vendors and other new players, as well as a flurry of activity around clinical data analysis software and the commercialization of a number of open source tools were the key trends in the bioinformatics community in 2012.

UK-based drug discovery services firm Molplex is using Microsoft’s cloud infrastructure to build its computational compound screening business.

This story originally ran on June 7.

TeraDiscoveries and Microsoft this week announced a partnership under which Microsoft will provide support and cloud computing time on its Windows Azure platform, which TeraDiscoveries will use to identify inhibitors of 25 biological targets.

Pages

An analysis of UK Biobank data finds hemochromatosis to be more prevalent than thought, according to the BBC.

An analysis finds that female biomedical researchers receive fewer prizes than male ones, and when they do win prizes, they are less prestigious.

In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.

Federal researchers tell the Los Angeles Times that the shutdown is causing missed research opportunities as they try to keep their experiments going.